Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T2DM
Study Details
Study Description
Brief Summary
In this multicenter, randomized, open-label, parallel-controlled, non-inferiority clinical trial, the efficacy and safety of insulin degludec/insulin aspart (IDegAsp) twice daily will be compared with degludec/insulin aspart (IDegAsp) once daily plus insulin aspart (IAsp) twice daily after 16weeks of treatment in patients with type 2 diabetes mellitus. This trial will enable primary assessment of the clinically relevant endpoint of a change in HbA1c.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
The objective of the current study is to investigate the efficacy and safety of IDegAsp twice daily compared with IDegAsp once daily plus IAsp twice daily for 16 weeks in patients with type 2 diabetes mellitus. The primary endpoint in this study is the change from baseline in HbA1c. Patients with type 2 diabetes who meet the entry criteria are planned for inclusion in this trial. Approximately 224 patients will be enrolled in the study. Patients who qualify will be randomized to IDegAsp group or IDegAsp + IAsp group. Duration of treatment includes 3-week screening period, 16-week treatment observation period and 1-week follow-up.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: IDegAsp group IDegAsp twice daily |
Drug: Insulin Degludec and Insulin Aspart Injection
To evaluate the efficacy and safety of the IDegAsp BID in T2DM
Other Names:
|
| Active Comparator: IDegAsp + IAsp group IDegAsp once daily plus IAsp twice daily |
Drug: Insulin Degludec and Insulin Aspart Injection
To evaluate the efficacy and safety of the IDegAsp BID in T2DM
Other Names:
Drug: Insulin Aspart Injection
To evaluate the efficacy and safety of the IDegAsp QD plus IAsp BID in T2DM
Other Names:
|
Outcome Measures
Primary Outcome Measures
- HbA1c [16 weeks]
the change from baseline in HbA1c after 16 weeks of treatment in all patients
Secondary Outcome Measures
- HbA1c response [16 weeks]
the percentage of patients with HbA1c < 7.0% in patients without definite hypoglycemia after 16 weeks of treatment
- Body weight [16 weeks]
the body weight change from baseline after 16 weeks of treatment
- Fasted Blood Glucose [16 weeks]
the change from baseline in fasting blood glucose after 16 weeks of treatment
- 7-Point Self-monitoring Blood Glucose [16 weeks]
the change from baseline in 7-point self-monitoring blood glucose profile after 16 weeks of treatment
- Continuous Glucose Monitoring [14-16 weeks]
the change from Baseline in Mean Glucose of CGM at Weeks 14-16 of Treatment
- Percentage of Time In Range [14-16 weeks]
the change from Baseline in Percentage of Readings in Target Range for Blood Glucose Values at Weeks 14-16 of Treatment
- Percentage of Time Below Range [14-16 weeks]
the change from Baseline in Percentage of Readings below Target Range for Blood Glucose Values at Weeks 14-16 of Treatment
- Percentage of Time Above Range [14-16 weeks]
the change from Baseline in Percentage of Readings above Target Range for Blood Glucose Values at Weeks 14-16 of Treatment
- Glucose Management Indicator [14-16 weeks]
the change from Baseline in estimated HbA1c at Weeks 14-16 of Treatment
- Glucose Variability [14-16 weeks]
Change from Baseline in Glucose Variability (Coefficient of Variation) of CGM at Weeks 14-16 of Treatment
- Time In Range [14-16 weeks]
the change from Baseline of time in Target Range for Blood Glucose Values at Weeks 14-16 of Treatment
- Time Below Range [14-16 weeks]
the change from Baseline of time below Target Range for Blood Glucose Values at Weeks 14-16 of Treatment
- Time Above Range [14-16 weeks]
the change from Baseline of time above Target Range for Blood Glucose Values at Weeks 14-16 of Treatment
Eligibility Criteria
Criteria
Inclusion Criteria:
-
- Informed consent has been obtained before any trial-related activities;
-
- Patients aged 18~75 years old (including 18 years old and 75 years old);
-
- Clinical diagnosis of type 2 diabetes ≥ 6 months according to WHO diagnostic criteria before screening;
-
- Use basal insulin once a day with or without other hypoglycemic drugs for at least 3 months before randomization;
-
- Glycated hemoglobin between 7.0%~10.0% (including the critical value);
-
- Body mass index (BMI)≤40.0kg/m2;
Exclusion Criteria:
-
- Suffering from type 1 diabetes, or special type of diabetes;
-
- Previously used premixed insulin or IDegAsp;
-
- Changes in concomitant medications that are expected to significantly interfere with glucose metabolism, such as systemic corticosteroids, beta-blockers, and monoamine oxidase (MAO) inhibitors;
-
- Known or suspected subjects are allergic to test drugs, excipients or related similar products and excipients;
-
- Cardiovascular and cerebrovascular disease, defined as: congestive heart failure (NYHA class III-IV), diagnosis of unstable angina pectoris, stroke and/or myocardial infarction within 6 months before screening; or planned/coronary artery , carotid artery, peripheral artery revascularization;
-
- According to the judgment of the investigator, repeated hypoglycemia perception impairment and severe hypoglycemia events occurred before screening;
-
- Abnormal and clinically significant hemoglobin laboratory test results;
-
- Hepatic insufficiency, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 2.5 times the upper limit of the normal range at screening; renal insufficiency, defined as (but not limited to) serum creatinine Levels ≥1.5mg/dL (132umol/L, men) and ≥1.4mg/dL (123umol/L, women), or massive proteinuria (>2 g/day);
-
- Uncontrolled/untreated hypertension (systolic blood pressure ≥160mmHg or diastolic blood pressure ≥100mmHg) before randomization;
-
- Two or more events of ketoacidosis or hyperglycemia and hyperosmolar state requiring hospitalization within 6 months prior to screening, or significant diabetic complications, such as symptomatic autonomic neuropathy, diabetic gastric mildew paralysis, proliferative retinopathy, etc. occured;
-
- According to the judgment of the investigator, significant changes in lifestyle are expected during the trial period, such as shift work (including persistent night/evening shift work) and highly irregular diet and living habits;
-
- Pregnant or breastfeeding women; those who have a pregnancy plan during the entire trial period and are unwilling to take one or more non-drug contraceptive measures (such as complete abstinence, contraceptive ring, partner ligation, etc.) during the trial;
-
- Participate in any clinical trial within the past 3 months;
-
- Those who are not suitable to participate in the trial according to the investigator's judgment, or any clinically significant disease or condition that the investigator believes may affect the results of the trial, such as: a history of hemolytic anemia or sickle cell anemia, a previous history of tumor or cancer Patients with a medical history, patients with a known history of alcohol, drug or drug abuse, blood transfusions or severe blood loss within the first 3 months of screening, or patients with poor adherence in the judgment of the investigator.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Hebei General Hospital | Shijiazhuang | Hebei | China | |
| 2 | Jilin University Sino-Japanese Friendship Hospital | Changchun | Jilin | China | |
| 3 | The Second Affiliated Medical College of Xi'an Jiaotong University | Xi'an | Shaanxi | China | |
| 4 | Beijing Boai Hospital | Beijing | China | ||
| 5 | Beijing Hospital | Beijing | China | ||
| 6 | Civil Aviation General Hospital | Beijing | China |
Sponsors and Collaborators
- Beijing Hospital
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- MLD-C-21003